These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1383982)

  • 1. Proarrhythmia in patients treated with moricizine.
    Ellenbogen KA; Welch WJ; Schoenfeld MH
    Pacing Clin Electrophysiol; 1992 Sep; 15(9):1240-3. PubMed ID: 1383982
    [No Abstract]   [Full Text] [Related]  

  • 2. Exercise induced fatal sinusoidal ventricular tachycardia secondary to moricizine.
    Nazari J; Bauman J; Pham T; Ivanovich L; Kehoe RF
    Pacing Clin Electrophysiol; 1992 Oct; 15(10 Pt 1):1421-4. PubMed ID: 1383951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiological evaluation of moricizine in patients with sustained ventricular tachyarrhythmias: low efficacy and high incidence of proarrhythmia.
    Bhandari AK; Lerman R; Ehrlich S; Sager P; Leon C; Widerhorn J; Cannom DS
    Pacing Clin Electrophysiol; 1993 Sep; 16(9):1853-61. PubMed ID: 7692418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moricizine-induced proarrhythmia.
    Seaborg SM; Cowan MD
    Clin Cardiol; 1992 Nov; 15(11):866-7. PubMed ID: 10969633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of proarrhythmic events during moricizine therapy and their relationship to ventricular function.
    Tschaidse O; Graboys TB; Lown B; Lampert S; Ravid S
    Am Heart J; 1992 Oct; 124(4):912-6. PubMed ID: 1529903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and risks of moricizine in inducible sustained ventricular tachycardia.
    Damle R; Levine J; Matos J; Greenberg S; Brooks R; Frumkin W; Goldberger J; Kadish AH
    Ann Intern Med; 1992 Mar; 116(5):375-81. PubMed ID: 1736770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exacerbation of congestive heart failure secondary to moricizine.
    O'Rangers EA; Kluger J
    Pharmacotherapy; 1992; 12(5):408-12. PubMed ID: 1437702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiologic response to moricizine in patients with sustained ventricular arrhythmias.
    Powell AC; Gold MR; Brooks R; Garan H; Ruskin JN; McGovern BA
    Ann Intern Med; 1992 Mar; 116(5):382-7. PubMed ID: 1736771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moricizine induced increase in pacing threshold.
    Girod JP; Marrouche N; Chen MS; Natale A
    Pacing Clin Electrophysiol; 2003 Jan; 26(1 Pt 1):110-1. PubMed ID: 12685150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and characteristics of proarrhythmia from moricizine (Ethmozine).
    Morganroth J; Pratt CM
    Am J Cardiol; 1989 Jan; 63(3):172-6. PubMed ID: 2642632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moricizine hydrochloride (Ethmozine).
    Dunn SL
    Crit Care Nurse; 1992 Apr; 12(4):61-3. PubMed ID: 1568380
    [No Abstract]   [Full Text] [Related]  

  • 12. Moricizine: a new agent for the treatment of ventricular arrhythmias.
    Grubb BP
    Am J Med Sci; 1991 Jun; 301(6):398-401. PubMed ID: 2039027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardioversion, defibrillation, and overdrive pacing of ventricular arrhythmias: the effect of moricizine in dogs with sustained monomorphic ventricular tachycardia.
    Avitall B; Hare J; Zander G; Lessila C; Dhala A; Deshpande S; Jazayeri M; Sra J; Akhtar M
    Pacing Clin Electrophysiol; 1993 Nov; 16(11):2092-7. PubMed ID: 7505920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible proarrhythmia with dronedarone.
    Rosman J; Hoffmeister P; Reynolds M; Peralta A
    J Cardiovasc Electrophysiol; 2013 Jan; 24(1):103-4. PubMed ID: 22812636
    [No Abstract]   [Full Text] [Related]  

  • 15. Moricizine and quality of life in the Cardiac Arrhythmia Suppression Trial II (CAST II).
    Brooks MM; Gorkin L; Schron EB; Wiklund I; Campion J; Ledingham RB
    Control Clin Trials; 1994 Dec; 15(6):437-49. PubMed ID: 7851106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
    Anderson JL; Platia EV; Hallstrom A; Henthorn RW; Buckingham TA; Carlson MD; Carson PE
    Circulation; 1994 Dec; 90(6):2843-52. PubMed ID: 7994829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moricizine for cardiac arrhythmias.
    Med Lett Drugs Ther; 1990 Nov; 32(830):99-100. PubMed ID: 2233510
    [No Abstract]   [Full Text] [Related]  

  • 18. Criteria for use of moricizine in adult inpatients and outpatients.
    Bennett TA; Trotter JM; Miller AB
    Clin Pharm; 1991 Nov; 10(11):873-5. PubMed ID: 1794224
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiarrhythmic Agent Induced Ventricular Tachycardia.
    Agrawal Y; Kalavakunta JK; Gupta V
    Am J Ther; 2017; 24(4):e487. PubMed ID: 27574940
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparison of the efficacy of moricizine and disopyramide in the treatment of ventricular extrasystoles].
    Fauchier JP; Babuty D; Rouesnel P; Cosnay P; Estepo J
    Arch Mal Coeur Vaiss; 1991 Apr; 84(4):553-60. PubMed ID: 1712193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.